Owners, management and financials
CVR: 41120681
DKK 3,676,788
Gross profit
Net result: DKK -2,096,400
Holding Fertility4U ApS (100%)
CVR · view owners
Martin Blomberg Jensen
CVR · view management
Active
Founded 28 January 2020
CVR · view overview
1 employee
Annual report 2025 · average
Director registered: Martin Blomberg Jensen
CVR · 28/01/2020
View the full event history
XY Therapeutics ApS is a Danish company of the type Anpartsselskab based in Charlottenlund, founded in 2020. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Martin Blomberg Jensen. The company is owned by Holding Fertility4U ApS. According to the 2025 annual report, the company had an average of 1 employee. In 2025, the company reported a gross profit of DKK 3,676,788 and a net result of DKK -2,096,400 compared with DKK -1,369,854 the year before. Equity in the 2025 report amounted to DKK -9,494,046.
Source: annual report 2025, Danish Business Authority
The financial health of XY Therapeutics ApS shows a concerning trend, with consistent losses over the past four years and negative equity reaching -9,494,046 DKK in 2025. Gross profit has fluctuated, peaking at 3,676,788 DKK in 2025, but the company has not generated any revenue, indicating reliance on external funding or grants. The increasing losses and deteriorating equity position raise concerns about sustainability, despite potential strengths in gross profit margins. As a relatively new player in the research and experimental development sector, the company faces significant challenges in establishing a stable financial foundation.
AI-generated summary · Generated 16/08/2026
Selskabets formål er at udvikle løsninger til at forstå og forbedre reproduktion og relaterede aktiviteter
Source: annual reports filed with the Danish Business Authority.
| Period | Gross Profit | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 202501/07/2024 – 30/06/2025 | 3.7 mio. | -2.1 mio. | 6 mio. | -9.5 mio. | 1 | |
| 202401/07/2023 – 30/06/2024 | 2.7 mio. | -1.4 mio. | 4.9 mio. | -7.4 mio. | 1 | |
| 202301/07/2022 – 30/06/2023 | 362 t. | -1.2 mio. | 4.9 mio. | -6 mio. | 2 | |
| 202201/07/2021 – 30/06/2022 | 627 t. | -2.4 mio. | 5.3 mio. | -4.9 mio. | 2 |
Compared to 1.039 companies in Forskning og eksperimentel udvikling inden for naturvidenskab og teknik
Comparison is based on industry median values
Screen owners and management against the Danish FSA's official PEP lists
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringThe CVR number of XY Therapeutics ApS is 41120681.
XY Therapeutics ApS is owned by Holding Fertility4U ApS.
The management of XY Therapeutics ApS consists of Martin Blomberg Jensen.
In 2025, XY Therapeutics ApS reported a gross profit of DKK 3,676,788.
XY Therapeutics ApS had an average of 1 employee in the 2025 financial year according to the annual report.
XY Therapeutics ApS was founded on 28 January 2020.
Claim this page to add your logo and social links. Free to get started.
XY Therapeutics ApS has published its annual report for 2025. Gross profit came to DKK 3,676,788, and the net result was DKK -2,096,400.
XY Therapeutics ApS has published its annual report for 2024. Gross profit came to DKK 2,680,629, and the net result was DKK -1,369,854.
XY Therapeutics ApS has published its annual report for 2023. Gross profit came to DKK 361,632, and the net result was DKK -1,152,205.
XY Therapeutics ApS has published its annual report for 2022. Gross profit came to DKK 626,764, and the net result was DKK -2,384,371.
XY Therapeutics ApS has published its interim report for the period January 28, 2020 – June 30, 2021.
As of February 2, 2021, Grant Thornton, Godkendt Revisionspartnerselskab has been appointed auditor of XY Therapeutics ApS.
As of January 28, 2020, Martin Blomberg Jensen is registered as director of XY Therapeutics ApS.
As of January 28, 2020, Holding Fertility4U ApS is registered as an owner of XY Therapeutics ApS with an ownership share of 100%.
XY Therapeutics ApS was founded on January 28, 2020.
Companies in the same industry and area
CVR 38716735
CVR 46299671
CVR 35190961
CVR 34626561
CVR 39297116
